Plasma-Based Materials: Naturally promote healing & reduce complications

Founded in 2007 as a spin out from Carnegie Mellon University in Pittsburgh, PA, Carmell Therapeutics has created a unique & highly innovative patented technology based on biologically-active materials manufactured from human blood plasma. These plasma-based materials (PBMs) contain a concentration of natural regenerative factors that promote healing in various clinical settings, reduce complications, and, as a result, save healthcare costs. Unlike previous approaches to delivering growth factors to injuries/surgeries, Carmell has patented the capability to create medical devices with pooled plasma that can be tuned as part of the manufacturing process to breakdown in the body over different periods of time (days, weeks or months) releasing the active biologics when the body needs them to accelerate healing. The company has successfully developed multiple forms, such as pastes, putties, scaffolds, plugs and screws, using pooled plasma from healthy donors with its proprietary cross linking process.

News

6/27/16   Carmell announces the awarding of a new U.S. Patent that covers the use of the Company’s plasma-based materials as drug delivery vehicles   June 24, 2016 – Pittsburgh, PA – Carmell Therapeutics announced that it has received its 8th U.S. patent. Patent number 9,364,503 covers broadly [...]
4/11/16   Dr. James Hart joins Carmell Therapeutics as new Chief Medical Officer   Pittsburgh, April 6, 2016 - Carmell Therapeutics announced today the appointment of Dr. James Hart as its new Chief Medical Officer (“CMO”). [...]
2/18/16   Randy Hubbell appointed as President and Chief Executive Officer   Pittsburgh, February 16, 2016 - Carmell Therapeutics announced today the appointment of Randy Hubbell to President and Chief Executive Officer. Former[...]
5/15/15   Carmell Therapeutics’ Plasma-Based Materials Shown to be Effective Antibiotic Delivery Vehicles   Carmell Therapeutics, a company developing novel products manufactured from blood plasma, today announced the publication of a paper in the journal Bi[...]